loader2
Partner With Us NRI

Company details

218.40
224.00
170.20
289.55
6M Return -16.87%
1Y Return 5.25%
Mkt Cap.(Cr) 2,118.25
Volume 22,599
Div Yield 0.05%
OI
-
OI Chg %
-
Volume 22,599

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Rapid Results

Q1FY23 Quarterly Result Announced for Gufic BioSciences Ltd.

Pharmaceuticals firm Gufic BioSciences announced Q1FY23 Result :

  • Critical Care Division:
    • Retained leadership position in Anti fungals & Anti bacterials
    • Launch of Dual Chamber Bag initially targeting Anti-infectives. Addressable market size is ~Rs. 3,000 crores
    • Critical Care segment faced headwinds due to reduced hospitalization and excess inventory in the channel. With the launch of Dual Chamber Bags and normalization of hospitalization we see growth coming back in the next few quarters
    • Entered Neurology with unique products, with a special task force, and dedicated training center to broaden the addressable market
  • Ferticare Division:
    • Dydrogesterone: This product is ready for launch. To de-risk, we have vertically integrated with our own API. Market size for this product is ~Rs. 700 crores growing at 60% YoY. We as a Company are planning annual sales of Rs. 20 Crs. in less than 2 years
    • Gufic has invested to develop recombinant alternatives to the urinary source of certain hormones which are critical in the treatment of infertility and thereby ensuring we will be independent of geopolitical as well as currency exchange risks and potential pitfalls in the next 15-18 months
    • Having the widest basket of products along with vertically integrated manufacturing and strong field presence, we intend to be among the top 3 players in the next 3 years in infertility market that is around ~Rs. 4,000 Crs. and growing at 15%

 

Result PDF

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 269.11 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 15,509.20 -8,578.65
LAST 3M 18,287.41 29,096.76
LAST 6M 90,792.99 -64,390.79
LAST 12M 213,883.43 -208,257.14
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
Aug 24, 2022 Dividend 10
Sep 09, 2021 Dividend 10
Nov 03, 2020 Dividend 5

Information

  • About Company
  • Company Info
  • Listing Info
24.81
75%
27.76
43.82%
43.31%
Description
  • Gufic Biosciences Ltd. is one of the pharma industry’s most rapidly growing companies. The company is classified as a small-cap company, with a current market capitalisation of Rs. 2,463 crore. The company was incorporated in the year 1984 with its registered office in Mumbai, Maharastra. Some of the key names in the company’s management are Pranav J Choksi, Shreyas K Patel, Rabi N Sahoo, Shrirang V Vaidya, and a few more. As of the third quarter of the financial year 2021-22, Gufic Biosciences’ net income was Rs. 21.04 crore.  Gufic Bio share is listed on both the National Stock Exchange and the Bombay Stock Exchange and is traded under the script name GUFICBIO.

    Gufic Biosciences is in the business and manufacturing of generic medicines, API formulations, and related services. The company operates through different segments such as Criti care, CritiCare life, personal care products, etc. The criti care lineup includes Rabol, Doxific, Tigefic-Plus, etc. The CritiCare life portfolio includes Gufivan-500. The personal care product lineup includes roll-on, stretch-nil, and so on. Whereas; Sulconazole, Micafungin, and Everolimus comes under API segment.

    The Gufic Biosciences’s Price-to-Earning (PE) ratio and Price-to-Book (PB) Ratio stand at 55.69 and 14.20, respectively. The company posted a Return on Earnings (ROE) of 29.22%. The dividend yield of the company is 0.04%. In the three quarters of the financial year 2021-22, the company’s net profit saw a downward trend, with figures of Rs. 31.21 crore, Rs. 23.34 crore, and Rs. 21.03 crore, respectively. In terms of shareholding patterns, promoters increased their position in the September quarter of FY 2021-22, while mutual funds trimmed their holdings slightly.

    On April 4, 2022, Gufic Bio share recorded an open price of Rs. 254.10 and made an intraday high of Rs. 267.80.  Gufic Bio’s share price also performed quite well in the last 12 months and reported 132.48% returns on the price chart. The 52-week high and low of Gufic Biosciences share price were Rs. 270 and Rs. 107.55. The share price of Gufic Biosciences is competing with CIPLA Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Dr Reddy’s Laboratories Ltd. 

    Disclaimer:- ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Read More

Registered Address

Shop-37 1st Flr Kamala Bhavan, Swami Nityanand Road Andheri(E, Mumbai, Maharashtra, 400069

Tel : 91-022-66919187/67261007/66919189
Email : info:guficbio.com
Website : http://www.guficbio.com

Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Nov
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 509079
NSE Code : GUFICBIO
Book Closure Date (Month) : Nov
BSE Group : B
ISIN : INE742B01025

ICICIdirect Gufic BioSciences Ltd FAQ

You can buy Gufic BioSciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Gufic BioSciences Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Oct 06, 2022 04:01 PM the closing price of Gufic BioSciences Ltd was ₹ 218.50.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 06, 2022 04:01 PM, the market cap of Gufic BioSciences Ltd stood at ₹ 2,118.25.
The latest PE ratio of Gufic BioSciences Ltd as of Oct 06, 2022 04:01 PM is 24.81
The latest PB ratio of Gufic BioSciences Ltd as of Oct 06, 2022 04:01 PM is 0.13
The 52-week high of Gufic BioSciences Ltd is ₹ 289.55 while the 52-week low is ₹ 170.20 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE